Read this company snapshot
Daily valuation snapshot
Allogene Therapeutics, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.46
- Market capitalization (USD)
- $504,416,686.26
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.16
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ALLO in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ALLO in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing ALLO with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.46 |
| Market capitalization (USD) | $504,416,686.26 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.16 |
No matching rows. Clear the filter to see all records.
Read ALLO's valuation metrics
Company size
Allogene Therapeutics, Inc. Common Stock's recorded market capitalization is $504,416,686.26. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
ALLO's recorded price-to-book ratio is 1.16. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Allogene Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about ALLO. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ALLO's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.